Search results - 20 results
Regulatory workshop on challenge strain development and GMP manufacture- A stakeholder meeting report.
Influenza Vaccines Influenza, Human Viruses Abstract: Within the Innovative Health Initiative (IHI) Inno4Vac CHIMICHURRI project, a regulatory workshop was organised on the development and manufacture of ...
Development of a monoclonal antibody sandwich ELISA for the determination of antigen content and quality in diphtheria vaccines.
control of diphtheria vaccines by both manufacturers and national control laboratories relies heavily on in vivo assays to confirm potency. As part of the VAC2VAC project we have developed a monoclonal ...
WP20 Regulatory update,
Publication Type: Scientific poster, presentation or proceeding Authors: Wim Van Molle Source: Inno4Vac 2nd annual meeting 2023, Lyon, France (2023) Service: Qualité des vaccins et produits ...
Regulatory progress and future plans
Publication Type: Scientific poster, presentation or proceeding Authors: Wim Van Molle Source: Inno4Vac 2nd annual meeting 2023, Lyon, France (2023) Service: Qualité des vaccins et produits ...
The IMI Inno4Vac project: a public-private partnership focussing on Innovations to accelerate vaccine development and manufacture
Publication Type: Scientific poster, presentation or proceeding Authors: Wim Van Molle Source: 2023 PDA BioManufacturing Conference Agility and Biomanufacturing Excellence to Meet Patients’ Needs, PDA, Issue PDA, Seville, Spain (2023) Service: Qualité de ...
Development of a multiplex-based immunoassay for the characterization of diphtheria, tetanus and acellular pertussis antigens in human combined DTaP vaccines.
vaccine release, notably for potency evaluation, still relies on animal use for several animal and human vaccines. In this context, the VAC2VAC project is a public-private consortium of 22 partners funded ...
Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial
comparable antibody responses to the full dose in people <55 years. Here, we report the safety and immunogenicity of a fractional dose regimen of the BNT162 b2 vaccine. REDU- VAC is a participant-blinded, ...
WP20 Regulatory. Workshop outcome, dissemination, gaps, and next steps: from models to showcases
Publication Type: Scientific poster, presentation or proceeding Authors: Wim Van Molle Source: Inno4Vac 1st Annual Meeting 2022, Siena, Italy (2022) Full text language: English Category: ...
Regulatory: outcomes of 3 STs Regulatory workshops and future plans
Publication Type: Scientific poster, presentation or proceeding Authors: Wim Van Molle Source: Inno4Vac 1st Annual Meeting 2022, Siena, Italy (2022) Service: Qualité des vaccins et produits ...
White paper recommendations summary
Publication Type: Scientific poster, presentation or proceeding Authors: Wim Van Molle Source: Inno4Vac ST2 (Chimichurri) Stakeholders meeting, Florence, Italy (2022) Service: Qualité des vaccins ...